Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IMNM
- Price
- 8.75
- Stock movement up
- +0.38 (3.97%)
- Company name
- Immunome Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 866.10M
- Ent value
- 752.52M
- Price/Sales
- 85.51
- Price/Book
- 4.03
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -30.42%
- 3 year return
- 22.37%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMNM does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 85.51 |
| Price to Book | 4.03 |
| EV to Sales | 74.29 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 87.05M |
| EPS (TTM) | -5.07 |
| FCF per share (TTM) | -1.54 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 10.13M |
| Gross profit (TTM) | 8.94M |
| Operating income (TTM) | -317.48M |
| Net income (TTM) | -305.35M |
| EPS (TTM) | -5.07 |
| EPS (1y forward) | -2.39 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 88.22% |
| Operating margin (TTM) | -3134.40% |
| Profit margin (TTM) | -3014.59% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 155.57M |
| Net receivables | 0.00 |
| Total current assets | 244.04M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 256.90M |
| Accounts payable | 3.52M |
| Short/Current long term debt | 2.72M |
| Total current liabilities | 39.53M |
| Total liabilities | 41.99M |
| Shareholder's equity | 214.91M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -86.19M |
| Capital expenditures (TTM) | 6.40M |
| Free cash flow (TTM) | -92.59M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -142.08% |
| Return on Assets | -118.86% |
| Return on Invested Capital | -141.91% |
| Cash Return on Invested Capital | -43.03% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 9.49 |
| Daily high | 9.96 |
| Daily low | 9.37 |
| Daily Volume | 367K |
| All-time high | 43.24 |
| 1y analyst estimate | 23.56 |
| Beta | 1.93 |
| EPS (TTM) | -5.07 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 17 Nov 2025 |
Downside potential
Loading...
Downside potential data
| IMNM | S&P500 | |
| Current price drop from All-time high | -76.99% | -1.46% |
| Highest price drop | -94.89% | -56.47% |
| Date of highest drop | 30 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -69.10% | -10.99% |
| Avg time to new high | 88 days | 12 days |
| Max time to new high | 1129 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
866.10M
Marketcap category
Small-cap
Description
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Employees
155
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page